The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer
We received valid questions from Duruisseaux et al. [1] regarding our previous report of differential efficacy among ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-rearranged non-small cell lung cancer (NSCLC) according to EML4-ALK fusion variants [2] . We agree that the benefits of local ablation therapy (LAT) and/or continuing crizotinib beyond progressive disease (CBPD) are considerable. The treatment line with crizotinib as well as subsequent second-generation ALK inhibitor treatment may affect overall survival (OS) in NSCLC patients.
To address these questions, we analyzed the survival, progression profile, and subsequent treatment of 44 crizotinib-treated patients from our prior analysis. Over a median follow-up period of 26.5 months, the median OS of the surviving patients was 36.3 months, while the systemic time to progression (TTP), defined from the first dose to the first documented objective progression, was 17.9 months. Similar to our previous data, the 2-year systemic TTP rate was significantly better for patients with variants 1/2/others (V1/2/others) than for those with variants 3a/b (V3a/b): 42.9% versus 10.6%, respectively (P ¼ 0.04). However, the 2-year OS rate was not significantly different between the V1/2/others (74.2%) and V3a/b (56.4%) groups (P ¼ 0.797). Table 1 summarizes the following patient information: progression profile, LAT usage, CBPD, crizotinib treatment line, brain metastasis at baseline, and subsequent second-generation ALK inhibitor treatment. The progression profile and proportion of patients receiving CBPD were not significantly different between the groups. Continuing CBPD was dependent on the clinician's decision about whether oligoprogression had occurred. As mentioned in our previous report, the proportions of heavily treated (secondline or higher) patients and those with brain metastasis at baseline were higher (75.0% versus 45.0%; P ¼ 0.042 and 37.5% versus 25.0%; P ¼ 0.375, respectively), and the proportion of patients receiving second-generation ALK inhibitors lower (29.2% versus 55.0%; P ¼ 0.083), in the V1/2/others group than in the V3a/b group. These factors could have affected the discrepancies in systemic TTP and OS between the groups. Most LATs used were brain or bone radiosurgery or radiotherapy; therefore, we assume that the higher proportion of LAT usage was associated with the higher frequency of brain metastases in the V1/2/others group.
All patients were confirmed to harbor the ALK translocation by FISH and were genotyped for EML4-ALK fusion variants by quantitative PCR, which can detect 28 known ALK rearrangement types, as indicated by Duruisseaux et al. [1] . In two patients in whom we could not identify the variant type, we sequenced the PCR products directly to identify EML-ALK fusion events.
In conclusion, we agree with Duruisseaux et al. [1] that our study is a small, single-institute, retrospective analysis of crizotinib sensitivity, and that larger comprehensive studies of EML-ALK-rearranged NSCLC cases are needed to determine the potential impact of ALK variants. However, we emphasize that the 2-year systemic TTP rate remained significantly different between the two groups after additional follow-up. The biological mechanisms underlying the heterogeneity of the outcomes following ALK TKI therapy are important but not understood [3, 4] . We hope our study can provide a basis for more precise stratification of ALK-driven lung cancers. Copy number alterations assessed at the single-cell level revealed mono-and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient Intra-tumour heterogeneity (ITH) is a common feature of many cancers and can facilitate tumour evolution. In the present study we assessed intra-tumour copy number heterogeneity using lowcoverage single-cell whole genome sequencing (scWGS) [1] . We determined copy number alterations (CNAs) in single cells of two areas of the primary tumour and from mediastinal lymph node, liver and adrenal metastases of a 79-year-old female stage IV small-cell lung carcinoma (SCLC) patient (supplementary Figure S1 , available at Annals of Oncology online). Copy number states in 2 Mb bins were assessed using a Hidden Markov Model in our custom developed pipeline AneuFinder [2, 3] . Of the 586 cells analysed, 346 passed quality control and were used for further analysis (supplementary methods, available at Annals of Oncology online). Merged scWGS data of each tumour used to generate bulk CNA patterns were highly similar to those generated by array-based comparative genomic hybridization on DNA isolated from the same five tissue samples (supplementary Figure  S2 , available at Annals of Oncology online).
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Unsupervised clustering of single cell genomes for copy number similarities revealed a high degree of ITH among single cells from the primary tumour, lymph node and adrenal metastases, but a much lower degree of ITH with a distinct CNA pattern in the liver metastasis ( Figure 1A) . The liver CNA pattern was characterized by a disomic, a trisomic and a tetrasomic part of chromosome 11, trisomy of 18, disomy of 22 and pentasomy of Xp ( Figure 1A) .
Previous studies have shown that metastasis development may occur from single [1] or multiple subclones of the primary tumour and from one metastatic site into another [4, 5] . To identify metastasis founder cells in this SCLC patient, we carried out hierarchical clustering of all sequenced primary tumour and metastasis cells. This revealed an overall intermixed pattern, especially for the primary tumours, the lymph node and adrenal metastases ( Figure 1B and supplementary Figure S3 , available at Annals of Oncology online). In contrast, the liver cells formed a distinct cluster that also contained two cells from primary tumour 1 (#59 and #82) and five adrenal metastasis cells (#26, #44, #74, #85 and #90), which all showed the liver-specific CNA pattern ( Figure  1C ). The strong association of a subset of primary tumour and adrenal metastasis single cells to the merged liver metastasis CNA data was supported by higher Pearson's correlation coefficients to the merged liver when compared with their own merged CNA pattern (supplementary Table S1 , available at Annals of Oncology online). Together, these data indicate that in this SCLC patient the liver-metastasis founder cells were present in the primary tumour as a minor clone. Hierarchical clustering of all sequenced primary tumour and metastasis cells ( Figure 1B and supplementary Figure S3 , available at Annals of Oncology online) and the results of the Pearson's correlation coefficients (supplementary Figure  1D , available at Annals of Oncology online) showed close association of the liver metastasis cells, which supports the low ITH in liver metastasis.
In conclusion, we found a high degree of CNA heterogeneity among cells of five distinct tumour locations in a single SCLC patient. A minority of the tumour cells of the primary tumour and the adrenal metastasis showed the dominant CNA pattern observed in liver metastasis cells. Our data suggest polyclonal seeding of the lymph node and adrenal metastases and a monoclonal seeding of the liver metastasis in this patient.
